08:53 AM EST, 02/26/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) rose 6.6% in U.S. pre-market trading on Wednesday after saying its Phase 1 trial investigating the safety and pharmacokinetics of its lead candidate Lucid-MS has been completed with no serious adverse events being reported.

According to a statement, a final safety review committee meeting concluded that Lucid-MS was well-tolerated with no safety concerns. The trial involved healthy adult participants.

Lucid-MS is a non-immunomodulatory, neuroprotective compound for the treatment of multiple sclerosis (MS). It has a unique mechanism of action and has been shown to directly stabilize the myelin sheath surrounding nerve fibers in preclinical models.

The company's shares were last seen up US$0.37 to US$5.95 in U.S. pre-market trading.